bupivacaine 0.25 % injection — Competitive Intelligence Brief

bupivacaine 0.25 % injection (bupivacaine 0.25 % injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide class). Area: Anesthesia.

marketed Local anesthetic (amide class) Voltage-gated sodium channels Anesthesia Small molecule

Target snapshot

bupivacaine 0.25 % injection (bupivacaine 0.25 % injection) — Ain Shams University. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bupivacaine 0.25 % injection TARGET	bupivacaine 0.25 % injection	Ain Shams University	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
carbamazepine oxcarbazepine	carbamazepine oxcarbazepine	Odense University Hospital	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels
Topical anesthetic	Topical anesthetic	University of Campinas, Brazil	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine 5% patch	Lidocaine 5% patch	Beijing Tiantan Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
levobupivacaine bolus dosing	levobupivacaine bolus dosing	Kuopio University Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Buffered Articaine Hydrochloride + Epinephrine	Buffered Articaine Hydrochloride + Epinephrine	Ohio State University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Articaine Hydrochloride + Epinephrine	Articaine Hydrochloride + Epinephrine	Ankara Yildirim Beyazıt University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide class) class)

1. Ain Shams University · 2 drugs in this class
2. Başakşehir Çam & Sakura City Hospital · 2 drugs in this class
3. TriHealth Inc. · 2 drugs in this class
4. Centre of Postgraduate Medical Education · 2 drugs in this class
5. Bozyaka Training and Research Hospital · 2 drugs in this class
6. Complejo Hospitalario Universitario de Granada · 1 drug in this class
7. Clinique Saint-Jean, Bruxelles · 1 drug in this class
8. Hospital Clínico Universitario de Valencia · 1 drug in this class
9. Fundacion Clinica Valle del Lili · 1 drug in this class
10. Federal University of Minas Gerais · 1 drug in this class